Autolus Therapeutics plc Current Assets
Autolus Therapeutics plc (AUTL) had Current Assets of $336.09 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-11
- 2026-06-30: Assets, Current $336.09M.
- 2026-03-31: Assets, Current $368.83M.
- 2025-12-31: Assets, Current $435.92M.
- 2025-09-30: Assets, Current $514.58M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $336.09M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $368.83M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $435.92M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $514.58M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $574.25M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $615.77M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $660.93M 10-K · filed 2026-03-27 |
| 2024-09-30 | $718.11M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $758.60M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $804.30M 10-Q · filed 2024-05-17 |
| 2023-12-31 | $275.30M 10-K · filed 2025-03-20 |
| 2023-09-30 | $308.38M 10-K · filed 2024-03-21 |
| 2023-06-30 | $355.37M 10-K · filed 2024-03-21 |
| 2023-03-31 | $393.88M 10-K · filed 2024-03-21 |
| 2022-12-31 | $425.77M 10-K · filed 2024-03-21 |
| 2022-09-30 | $212.31M 10-K · filed 2024-03-21 |
| 2022-06-30 | $258.96M 10-K · filed 2024-03-21 |
| 2022-03-31 | $309.46M 10-K · filed 2024-03-21 |
| 2021-12-31 | $346.95M 20-F · filed 2023-03-07 |
| 2021-03-31 | $288.06M 6-K · filed 2021-05-06 |
| 2020-12-31 | $196.98M 20-F · filed 2022-03-10 |
| 2020-09-30 | $228.87M 6-K · filed 2020-11-05 |
| 2020-06-30 | $248.73M 6-K · filed 2020-08-06 |
| 2020-03-31 | $280.94M 6-K · filed 2020-05-07 |
| 2019-12-31 | $249.26M 20-F · filed 2021-03-04 |
| 2019-09-30 | $260.18M 6-K · filed 2019-11-07 |
| 2019-06-30 | $292.71M 6-K · filed 2019-08-08 |
| 2018-12-31 | $232.97M 20-F · filed 2020-03-03 |
| 2018-09-30 | $259.28M 20-F · filed 2019-02-25 |
| 2017-09-30 | $142.48M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |